Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
In Vitro Enzyme Assay from US Patent US11236089: "Substituted pyrrolopyridines as ATR inhibitors"
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µM
Receptor Activity Assay from US Patent US10633388: "Pyrazolopyrimidone derivatives and methods of use thereof"
Assay data:14 Active, 11 Activity ≤ 1 nM, 14 Activity ≤ 1 µM, 14 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition Assay from Article 10.1111/cbdd.12241: "Synthesis and evaluation of novel oleanolic acid derivatives as potential antidiabetic agents."
Assay data:3 Active, 17 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Binding Assay from US Patent US8501708: "Adenosine compounds and their use thereof"
Assay data:18 Active, 17 Activity ≤ 1 µM, 18 Tested
GPa Inhibition Assay from Article 10.1016/j.bmc.2009.04.049: "Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives."
Assay data:1 Active, 9 Tested
Determination of Inhibitory Potencies by Coupled ATPase Activity Assay from Article 10.1016/j.bmc.2008.12.010: "Structure-based virtual screening for novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase and their experimental evaluation."
Assay data:2 Active, 19 Tested
Determination of Inhibitory Potencies by Coupled ATPase Activity Assay from Article 10.1016/j.bmc.2009.07.075: "Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase."
Assay data:8 Active, 2 Activity ≤ 1 µM, 12 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Enzyme Inhibition Assay from Article 10.1016/j.bmc.2009.08.060: "Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors."
Assay data:3 Active, 1 Activity ≤ 1 µM, 5 Tested
Glycogen Phosphorylase Enzyme Assay from Article 10.1016/j.bmc.2009.08.045: "Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase."
Assay data:11 Active, 1 Activity ≤ 1 µM, 32 Tested
In Vitro Binding Assay from Article 10.1021/jm0498194: "Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators."
Assay data:25 Active, 1 Activity ≤ 1 nM, 25 Activity ≤ 1 µM, 25 Tested
Enzyme Inhibition Assay from Article 10.1021/jm8000949: "Naturally Occurring Pentacyclic Triterpenes as Inhibitors of Glycogen Phosphorylase: Synthesis, Structure-Activity Relationships, and X-ray Crystallographic Studies."
Assay data:1 Active, 23 Tested
Enzyme Inhibition Assay from Article 10.1021/jm061471k: "Selective inhibition of carboxylesterases by isatins, indole-2,3-diones."
Assay data:40 Active, 23 Activity ≤ 1 µM, 65 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Enzyme Inhibition Assay from Article 10.1021/jm049011j: "Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases."
Assay data:36 Active, 30 Activity ≤ 1 µM, 60 Tested
Enzyme Inhibition Assay from Article 10.1016/j.bmcl.2004.12.081: "Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase."
Assay data:44 Active, 38 Activity ≤ 1 µM, 51 Tested
Enzyme Inhibition Assay from Article 10.1016/j.bmcl.2007.07.011: "Discovery of selective imidazole-based inhibitors of mammalian 15-lipoxygenase: highly potent against human enzyme within a cellular environment."
Assay data:31 Active, 29 Activity ≤ 1 µM, 36 Tested
In Vitro Inhibition of NEP from Article 10.1021/jm0005454: "Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP)."
Assay data:29 Active, 1 Activity ≤ 1 nM, 29 Activity ≤ 1 µM, 29 Tested
In Vitro Enzyme Inhibition Assay and Bone-Resorption Assay from Article 10.1016/j.bmcl.2007.03.028: "Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core."
Assay data:10 Active, 5 Activity ≤ 1 nM, 10 Activity ≤ 1 µM, 10 Tested
Enzyme Inhibition Assay and Bone Resorption Assay from Article 10.1021/jm0504961: "Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity."
Assay data:5 Active, 1 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 5 Tested
Enzyme Inhibition Assay from Article 10.1021/jm0504961: "Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity."
Assay data:6 Active, 1 Activity ≤ 1 nM, 6 Activity ≤ 1 µM, 7 Tested
Enzyme Inhibition Assay from Article 10.1021/jm051059p: "Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K."
Assay data:36 Active, 3 Activity ≤ 1 nM, 36 Activity ≤ 1 µM, 36 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on